ASP Isotopes (ASPI) Continue to Slump Despite Response to Short Seller Report – Hagens Berman

ASPI Investors with Losses Encouraged to Contact the Firm

/EIN News/ -- SAN FRANCISCO, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Shares of ASP Isotopes Inc. (NASDAQ: ASPI) have continue their downward spiral falling 16% over the past five days, despite the company having issued a rebuttal to a scathing report from activist short-seller Fuzzy Panda Research. The stock price trades at $4.52 per share, marking a 40% decline since the release of the short seller report late last month.

The Fuzzy Panda report, published on November 26, accused ASP Isotopes of misleading investors about the viability of its nuclear fuel technologies. These allegations have not only sent the company's stock spiraling but have also triggered a securities class action lawsuit filed in the U.S. District Court for the Southern District of New York.

Hagens Berman urges investors in ASP Isotopes who suffered substantial losses to submit your losses now.
Class Period: Oct. 30, 2024 – Nov. 26, 2024
Lead Plaintiff Deadline: Feb. 3, 2025
Visit: www.hbsslaw.com/investor-fraud/aspi
Contact the Firm Now: ASPI@hbsslaw.com
844-916-0895

ASP Isotopes Inc. (ASPI) Securities Class Action:

The lawsuit claims that ASP Isotopes overstated the effectiveness of its enrichment technologies, including its Aerodynamic Separation Process (ASP) and Quantum Enrichment, and misled investors about the potential of its high-assay low-enriched uranium facility.

The Fuzzy Panda report, which alleges that ASPI's technology is "outdated and unlikely to be commercially viable," has further fueled investor concerns. The report contends that the company employs "old, disregarded laser enrichment technology" to falsely portray itself as a cutting-edge player in the nuclear fuel industry. It also claims that former executives of Centrus Energy had deemed ASPI's technology "virtually worthless."

Following the release of the report, ASPI's stock price plunged 23% in a single trading day.

The events have prompted shareholder rights firm Hagens Berman to investigate potential investor losses.

“We are investigating whether ASP Isotopes misled investors about the true potential and viability of its enrichment technologies," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation.

If you invested in ASP Isotopes or have knowledge that may assist the firm’s investigation, submit your losses now »

If you’d like more information and answers to frequently asked questions about the ASP Isotopes case and our investigation, read more »

Whistleblowers: Persons with non-public information regarding ASP Isotopes should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email ASPI@hbsslaw.com.

About Hagens Berman
Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.

Contact:
Reed Kathrein, 844-916-0895